10 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Voir le projet
34
Participants partenaires
TERMINÉ
Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy (AETIONOMY)
Date du début: 1 janv. 2014, Date de fin: 31 déc. 2018,
IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and (II) the focused application of this pipeline to derive clinically significant mechanistic taxonomies of neurodegenerativ ...
Voir le projet
20
Participants partenaires
TERMINÉ
Intelligent Assessment of Pharmaceutical in the Environment (IPIE)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Voir le projet
29
Participants partenaires
TERMINÉ
Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Voir le projet
22
Participants partenaires
TERMINÉ
Oral biopharmaceutics tools (ORBITO)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Voir le projet
28
Participants partenaires
TERMINÉ
European Patients' Academy on Therapeutic Innovation (EUPATI)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,
"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Voir le projet
33
Participants partenaires
TERMINÉ
European Medicines Research Training Network (EMTRAIN)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2016,
EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Voir le projet
32
Participants partenaires
TERMINÉ
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Voir le projet
38
Participants partenaires
TERMINÉ
Understanding chronic pain and improving its treatment (EUROPAIN)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,
We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational research which will: 1) increase the understanding of chronic pain mechanisms; 2)facilitate the development of novel analgesic drugs; and 3) improve the treatment of chronic pain patients.Nineteen researchers drawn from the London Pain Consortium, the Danish Pain Re ...
Voir le projet
29
Participants partenaires
TERMINÉ
Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes (IMIDIA)
Date du début: 1 févr. 2010, Date de fin: 30 sept. 2015,
An absolute or relative loss of beta-cell mass and function underlie the development of type I and type 2 diabetes.Preventing beta-cell demise or restoring their number and function is a major therapeutic goal. However,development of novel diagnostic and prognostic tools, and of novel therapeutic modalities, is hampered by the limited knowledge of the molecular pathways that control beta-cell demi ...
Voir le projet